Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice

Meng,Xianying; Zhang,Qiang; Zheng,Guibin; Pang,Renzhu; Hua,Tebo; Yang,Shuai; Li,Jie

doi:10.3892/ol.2014.2050

Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice

Authors:
- Xianying Meng
- Qiang Zhang
- Guibin Zheng
- Renzhu Pang
- Tebo Hua
- Shuai Yang
- Jie Li
View Affiliations

Affiliations: Department of Thyroid Surgery, First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Geratology, First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: April 9, 2014 https://doi.org/10.3892/ol.2014.2050
Pages: 2053-2058

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the antitumor effect of celecoxib (CXB) combined with doxorubicin (DOX) on the subcutaneous xenograft tumor of medullary thyroid carcinoma in nude mice, and to analyze the possible mechanism of action. Nude mice with xenografted medullary thyroid carcinoma (MTC) were randomly divided into the control, CXB, DOX and DOX plus CXB groups, and the drug treatment was administered for three weeks. It was found that the tumor inhibition rates and the apoptosis index in the treatment groups were higher than in the control group (P<0.01), and that these values were higher in the combination group compared with the single‑drug group (P<0.01). DOX alone upregulated the cyclooxygenase‑2 and multidrug‑resistance 1 expression levels, and the combination of CXB and DOX or CXB alone notably decreased the expression level of the two proteins compared with no treatment. The results of the present study provide evidence that a combination of DOX and CXB is a potential drug candidate for the treatment of MTC.

View Figures

View References

1	Zhang J, Wang Y, Li D and Jing S: Notch and TGF-β/Smad3 pathways are involved in the interaction between cancer cells and cancer-associated fibroblasts in papillary thyroid carcinoma. Tumour Biol. 35:379–385. 2014.
2	Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006.
3	Tavares MR, Toledo SP, Montenegro FL, et al: Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2. Clinics (Sao Paulo). 67(Suppl 1): 149–154. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tavares MR, Michaluart P Jr, Montenegro F, et al: Skip metastases in medullary thyroid carcinoma: a single-center experience. Surg Today. 38:499–504. 2008. View Article : Google Scholar : PubMed/NCBI
5	Machens A, Lorenz K and Dralle H: Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pre-therapeutic calcitonin levels. Ann Surg. 250:305–310. 2009. View Article : Google Scholar
6	Singal PK, Li T, Kumar D, et al: Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem. 207:77–86. 2000. View Article : Google Scholar : PubMed/NCBI
7	Carvalho C, Santos RX, Cardoso S, et al: Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 16:3267–3285. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2:48–58. 2002. View Article : Google Scholar : PubMed/NCBI
9	Silber JH and Barber G: Doxorubicin-induced cardiotoxicity. N Engl J Med. 333:1359–1360. 1995. View Article : Google Scholar : PubMed/NCBI
10	King PD and Perry MC: Hepatotoxicity of chemotherapy. Oncologist. 6:162–176. 2001. View Article : Google Scholar : PubMed/NCBI
11	Wang S, Konorev EA, Kotamraju S, et al: Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. Intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem. 279:25535–25543. 2004. View Article : Google Scholar : PubMed/NCBI
12	Mukhopadhyay P, Rajesh M, Bátkai S, et al: Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol. 296:1466–1483. 2009. View Article : Google Scholar : PubMed/NCBI
13	Das A, Durrant D, Mitchell C, Mayton E, et al: Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA. 107:18202–18207. 2009. View Article : Google Scholar : PubMed/NCBI
14	Dayton A, Selvendiran K, Meduru S, Khan M, et al: Amelioration of doxorubicin-induced cardiotoxicity by an anticancer-antioxidant dual-function compound, HO-3867. J Pharmacol Exp Ther. 339:350–357. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chen C, Xu W and Wang CM: Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells. Leuk Lymphoma. 54:2517–2522. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ponthan F, Wickström M, Gleissman H, et al: Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res. 13:1036–1044. 2007. View Article : Google Scholar : PubMed/NCBI
17	Dai ZJ, Gao J, Li ZF, et al: In vitro and in vivo antitumor activity of Scutellaria barbate extract on murine liver cancer. Molecules. 16:4389–4400. 2001.PubMed/NCBI
18	Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 26:4708–4713. 2008. View Article : Google Scholar : PubMed/NCBI
19	Salgia R, Sherman S, Hong DS, Ng CS, et al: A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). J Clin Oncol. 26(15S): 35222008.
20	Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 27:3794–3801. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 28:767–772. 2010. View Article : Google Scholar : PubMed/NCBI
22	Zatelli MC, Luchin A, Piccin D, et al: Cyclooxygenase-2 Inhibitors Reverse Chemoresistance Phenotype in Medullary Thyroid Carcinoma by a Permeability Glycoprotein-Mediated Mechanism. J Clin Endocrinol Metab. 90:5754–5760. 2005. View Article : Google Scholar
23	Vivaldi A, Ciampi R, Tacito A, et al: Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Mol Cell Endocrinol. 355:41–48. 2012. View Article : Google Scholar : PubMed/NCBI
24	Hoff AO and Hoff PM: Medullary thyroid carcinoma. Hematol Oncol Clin North Am. 21:475–488. 2008. View Article : Google Scholar
25	Massart C, Gibassier J, Lucas C, et al: Expression of the MDR1 gene in five human cell lines of medullary thyroid cancer and reversion of the resistance to doxorubicine by ciclosporin A and verapamil. Bull Cancer. 83:39–45. 1996.(In French).
26	Breier A, Barancík M, Sulová Z and Uhrík B: P-glycoprotein - implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 5:457–468. 2005. View Article : Google Scholar : PubMed/NCBI
27	Doyle L and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
28	Johnstone RW, Ruefli AA and Smyth MJ: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 25:1–6. 2010. View Article : Google Scholar : PubMed/NCBI
29	Patel VA, Dunn MJ and Sorokin A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 277:38915–38920. 2002. View Article : Google Scholar : PubMed/NCBI
30	Jendrossek V: Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 322:313–324. 2013. View Article : Google Scholar